Cancer progress, a broader pipeline and vaccine expansion help MRNA rebuild beyond COVID-19, but can oncology drive its next ...

The average one-year price target for Arcturus Therapeutics Holdings (NASDAQGM:ARCT) has been revised to $22.75 / share. This is an increase of 14.69% from the prior estimate of $19.83 dated August 25 ...

Moderna (MRNA) closed at $146.69 in the latest trading session, marking a +1.89% move from the prior day. The stock outperformed the S&P 500, which registered a daily loss of 0.48%. At the same time, ...

Moderna built an artificial intelligence that reads a patient’s tumor and decides what that patient’s medicine should be.

Moderna and Merck's Phase 3 melanoma vaccine trial showed positive results, but full data and FDA approval are still pending ...

Moderna's recent success in a phase 3 clinical trial for its personalized cancer vaccine was a breakthrough. This product ...

Doctors discovered that Johnson had stage 2B triple-negative breast cancer, a rare and aggressive form. They treated her with ...

President Stephen Hoge said the company’s recently announced positive Phase III results for its investigational personalized cancer vaccine, intismeran, in adjuvant melanoma support a broader effort ...

Forecasts vary widely depending on how the category is drawn, but they point the same way. Global Market Insights sizes the market at about $4.0 billion in 2026 and projects approximately $43.9 ...

Florida pharmacies and clinics are now offering updated flu and COVID vaccines for the 2026-27 respiratory illness season, ...

Following their blowout win in melanoma last month, Merck and Moderna are leading the way among a new crop of personalized ...

A year to the day after the Trump administration slashed $500 million in funding from mRNA-based programs, the FDA approved ...